181 related articles for article (PubMed ID: 20500769)
1. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors.
Wild PJ; Meyer S; Bataille F; Woenckhaus M; Ameres M; Vogt T; Landthaler M; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Arch Dermatol; 2006 Apr; 142(4):471-6. PubMed ID: 16618867
[TBL] [Abstract][Full Text] [Related]
3. A potential predictive marker for response to interferon in malignant melanoma.
Wild PJ; Meyer S; Landthaler M; Hofstaedter F; Bosserhoff AK
J Dtsch Dermatol Ges; 2007 Jun; 5(6):456-9. PubMed ID: 17537037
[TBL] [Abstract][Full Text] [Related]
4. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.
Rangel J; Torabian S; Shaikh L; Nosrati M; Baehner FL; Haqq C; Leong SP; Miller JR; Sagebiel RW; Kashani-Sabet M
J Clin Oncol; 2006 Oct; 24(28):4565-9. PubMed ID: 17008696
[TBL] [Abstract][Full Text] [Related]
7. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.
Behrmann I; Wallner S; Komyod W; Heinrich PC; Schuierer M; Buettner R; Bosserhoff AK
Am J Pathol; 2003 Aug; 163(2):683-90. PubMed ID: 12875987
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
9. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
Busch C; Geisler J; Lillehaug JR; Lønning PE
Eur J Cancer; 2010 Jul; 46(11):2127-33. PubMed ID: 20541396
[TBL] [Abstract][Full Text] [Related]
10. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma.
Thies A; Schachner M; Berger J; Moll I; Schulze HJ; Brunner G; Schumacher U
J Pathol; 2004 Aug; 203(4):933-9. PubMed ID: 15258996
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of galectin-3 in primary cutaneous melanoma.
Buljan M; Šitum M; Tomas D; Milošević M; Krušlin B
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1174-81. PubMed ID: 21175876
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin as a molecular prognostic marker for melanoma.
Rangel J; Nosrati M; Torabian S; Shaikh L; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Cancer; 2008 Jan; 112(1):144-50. PubMed ID: 18023025
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
14. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
Dai DL; Martinka M; Li G
J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
18. The role of nm23 in melanoma progression and its prognostic significance.
Betke H; Korabiowska M; Brinck U; Trybus-Gałuszka H; Kellner S; Okoń K; Stachura J; Droese M
Pol J Pathol; 1998; 49(2):93-6. PubMed ID: 9798412
[TBL] [Abstract][Full Text] [Related]
19. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.
Salti GI; Manougian T; Farolan M; Shilkaitis A; Majumdar D; Das Gupta TK
Cancer Res; 2000 Sep; 60(18):5012-6. PubMed ID: 11016620
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma.
Oba J; Nakahara T; Hayashida S; Kido M; Xie L; Takahara M; Uchi H; Miyazaki S; Abe T; Hagihara A; Moroi Y; Furue M
J Am Acad Dermatol; 2011 Dec; 65(6):1152-60. PubMed ID: 21700362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
